Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 75 entries
Sorted by: Best Match Show Resources per page
Impact of an SMS reminder service on outpatient clinic attendance rates by patients with HIV followed-up at Pointe-à-Pitre University Hospital.

Patient preference and adherence

Zebina M, Melot B, Binachon B, Ouissa R, Lamaury I, Hoen B.
PMID: 30774317
Patient Prefer Adherence. 2019 Jan 25;13:215-221. doi: 10.2147/PPA.S182186. eCollection 2019.

OBJECTIVE: By the end of 2014, 23% of people living with HIV (PWHIV) who had had a scheduled appointment at our outpatient clinic had not attended. We implemented an SMS reminder service and assessed its impact on medical consultation-attendance...

Cite
Zebina M, Melot B, Binachon B, et al. Impact of an SMS reminder service on outpatient clinic attendance rates by patients with HIV followed-up at Pointe-à-Pitre University Hospital. Patient Prefer Adherence. 2019;13:215-221doi: 10.2147/PPA.S182186.
Zebina, M., Melot, B., Binachon, B., Ouissa, R., Lamaury, I., & Hoen, B. (2019). Impact of an SMS reminder service on outpatient clinic attendance rates by patients with HIV followed-up at Pointe-à-Pitre University Hospital. Patient preference and adherence, 13215-221. https://doi.org/10.2147/PPA.S182186
Zebina, Marine, et al. "Impact of an SMS reminder service on outpatient clinic attendance rates by patients with HIV followed-up at Pointe-à-Pitre University Hospital." Patient preference and adherence vol. 13 (2019): 215-221. doi: https://doi.org/10.2147/PPA.S182186
Zebina M, Melot B, Binachon B, Ouissa R, Lamaury I, Hoen B. Impact of an SMS reminder service on outpatient clinic attendance rates by patients with HIV followed-up at Pointe-à-Pitre University Hospital. Patient Prefer Adherence. 2019 Jan 25;13:215-221. doi: 10.2147/PPA.S182186. eCollection 2019. PMID: 30774317; PMCID: PMC6354684.
Copy Download .nbib Format: NLM
Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study.

BMJ open respiratory research

O'Neill K, Moran F, Tunney MM, Elborn JS, Bradbury I, Downey DG, Rendall J, Bradley JM.
PMID: 28123751
BMJ Open Respir Res. 2017 Jan 12;4(1):e000168. doi: 10.1136/bmjresp-2016-000168. eCollection 2017.

BACKGROUND: Streamlining the timing of treatments in cystic fibrosis (CF) is important to optimise adherence while ensuring efficacy. The optimal timing of treatment with hypertonic saline (HTS) and airway clearance techniques (ACT) is unknown.OBJECTIVES: This study hypothesised that HTS...

Cite
O'Neill K, Moran F, Tunney MM, et al. Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study. BMJ Open Respir Res. 2017;4(1):e000168doi: 10.1136/bmjresp-2016-000168.
O'Neill, K., Moran, F., Tunney, M. M., Elborn, J. S., Bradbury, I., Downey, D. G., Rendall, J., & Bradley, J. M. (2017). Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study. BMJ open respiratory research, 4(1), e000168. https://doi.org/10.1136/bmjresp-2016-000168
O'Neill, Katherine, et al. "Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study." BMJ open respiratory research vol. 4,1 (2017): e000168. doi: https://doi.org/10.1136/bmjresp-2016-000168
O'Neill K, Moran F, Tunney MM, Elborn JS, Bradbury I, Downey DG, Rendall J, Bradley JM. Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study. BMJ Open Respir Res. 2017 Jan 12;4(1):e000168. doi: 10.1136/bmjresp-2016-000168. eCollection 2017. PMID: 28123751; PMCID: PMC5253607.
Copy Download .nbib Format: NLM
Principles of biomechanics in oral implantology.

Medicine and pharmacy reports

Manea A, Bran S, Dinu C, Rotaru H, Barbur I, Crisan B, Armencea G, Onisor F, Lazar M, Ostas D, Baciut M, Vacaras S, Mitre I, Crisan L, Muresan O, Roman R, Baciut G.
PMID: 31989104
Med Pharm Rep. 2019 Dec;92:S14-S19. doi: 10.15386/mpr-1512. Epub 2019 Dec 15.

BACKGROUND AND AIMS: The principles of biomechanics comprise all the interactions between the body (tissues) and the forces acting upon it (directly or via different medical devices). Besides the mechanical aspects, the tissues response is also studied. Understanding and...

Cite
Manea A, Bran S, Dinu C, et al. Principles of biomechanics in oral implantology. Med Pharm Rep. 2019;92:S14-S19doi: 10.15386/mpr-1512.
Manea, A., Bran, S., Dinu, C., Rotaru, H., Barbur, I., Crisan, B., Armencea, G., Onisor, F., Lazar, M., Ostas, D., Baciut, M., Vacaras, S., Mitre, I., Crisan, L., Muresan, O., Roman, R., & Baciut, G. (2019). Principles of biomechanics in oral implantology. Medicine and pharmacy reports, 92S14-S19. https://doi.org/10.15386/mpr-1512
Manea, Avram, et al. "Principles of biomechanics in oral implantology." Medicine and pharmacy reports vol. 92 (2019): S14-S19. doi: https://doi.org/10.15386/mpr-1512
Manea A, Bran S, Dinu C, Rotaru H, Barbur I, Crisan B, Armencea G, Onisor F, Lazar M, Ostas D, Baciut M, Vacaras S, Mitre I, Crisan L, Muresan O, Roman R, Baciut G. Principles of biomechanics in oral implantology. Med Pharm Rep. 2019 Dec;92:S14-S19. doi: 10.15386/mpr-1512. Epub 2019 Dec 15. PMID: 31989104; PMCID: PMC6978931.
Copy Download .nbib Format: NLM
Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination.

Arthritis & rheumatology (Hoboken, N.J.)

Connolly CM, Ruddy JA, Boyarsky BJ, Barbur I, Werbel WA, Geetha D, Garonzik-Wang JM, Segev DL, Christopher-Stine L, Paik JJ.
PMID: 34346185
Arthritis Rheumatol. 2022 Jan;74(1):28-32. doi: 10.1002/art.41924. Epub 2021 Dec 03.

OBJECTIVE: To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2-dose SARS-CoV-2 messenger RNA (mRNA) vaccination.METHODS: RMD patients (n = 1,377) who received 2-dose SARS-CoV-2 mRNA vaccination between December 16, 2020...

Cite
Connolly CM, Ruddy JA, Boyarsky BJ, et al. Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. Arthritis Rheumatol. 2021;74(1):28-32doi: 10.1002/art.41924.
Connolly, C. M., Ruddy, J. A., Boyarsky, B. J., Barbur, I., Werbel, W. A., Geetha, D., Garonzik-Wang, J. M., Segev, D. L., Christopher-Stine, L., & Paik, J. J. (2022). Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. Arthritis & rheumatology (Hoboken, N.J.), 74(1), 28-32. https://doi.org/10.1002/art.41924
Connolly, Caoilfhionn M, et al. "Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination." Arthritis & rheumatology (Hoboken, N.J.) vol. 74,1 (2022): 28-32. doi: https://doi.org/10.1002/art.41924
Connolly CM, Ruddy JA, Boyarsky BJ, Barbur I, Werbel WA, Geetha D, Garonzik-Wang JM, Segev DL, Christopher-Stine L, Paik JJ. Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. Arthritis Rheumatol. 2022 Jan;74(1):28-32. doi: 10.1002/art.41924. Epub 2021 Dec 03. PMID: 34346185.
Copy Download .nbib Format: NLM
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research

Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W.
PMID: 34598946
Clin Cancer Res. 2021 Dec 15;27(24):6677-6686. doi: 10.1158/1078-0432.CCR-21-2199. Epub 2021 Oct 01.

PURPOSE: The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic PATIENTS AND METHODS: Patients had progressed after next-generation androgen receptor-directed and taxane-based therapies for...

Cite
Loehr A, Patnaik A, Campbell D, et al. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clin Cancer Res. 2021;27(24):6677-6686doi: 10.1158/1078-0432.CCR-21-2199.
Loehr, A., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., Zhang, J., Piulats, J. M., Hussain, A., Ryan, C. J., Merseburger, A. S., Daugaard, G., Heidenreich, A., Fizazi, K., Higano, C. S., Krieger, L. E., Sternberg, C. N., Watkins, S. P., Despain, D., Simmons, A. D., Dowson, M., Golsorkhi, T., Chowdhury, S., & Abida, W. (2021). Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6677-6686. https://doi.org/10.1158/1078-0432.CCR-21-2199
Loehr, Andrea, et al. "Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6677-6686. doi: https://doi.org/10.1158/1078-0432.CCR-21-2199
Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clin Cancer Res. 2021 Dec 15;27(24):6677-6686. doi: 10.1158/1078-0432.CCR-21-2199. Epub 2021 Oct 01. PMID: 34598946; PMCID: PMC8678310.
Copy Download .nbib Format: NLM
Out-of-Pocket Spending for Asthma-Related Care Among Commercially Insured Patients, 2004-2016.

The journal of allergy and clinical immunology. In practice

Sinaiko AD, Gaye M, Wu AC, Bambury E, Zhang F, Xu X, Wharam JF, Galbraith AA.
PMID: 34481128
J Allergy Clin Immunol Pract. 2021 Dec;9(12):4324-4331.e7. doi: 10.1016/j.jaip.2021.07.054. Epub 2021 Sep 01.

BACKGROUND: Out-of-pocket (OOP) health care costs can cause financial burden and deferred care for many Americans. Little is known about OOP spending for asthma-related care among the commercially insured.OBJECTIVES: To analyze OOP spending for asthma-related care overall, across types...

Cite
Sinaiko AD, Gaye M, Wu AC, et al. Out-of-Pocket Spending for Asthma-Related Care Among Commercially Insured Patients, 2004-2016. J Allergy Clin Immunol Pract. 2021;9(12):4324-4331.e7doi: 10.1016/j.jaip.2021.07.054.
Sinaiko, A. D., Gaye, M., Wu, A. C., Bambury, E., Zhang, F., Xu, X., Wharam, J. F., & Galbraith, A. A. (2021). Out-of-Pocket Spending for Asthma-Related Care Among Commercially Insured Patients, 2004-2016. The journal of allergy and clinical immunology. In practice, 9(12), 4324-4331.e7. https://doi.org/10.1016/j.jaip.2021.07.054
Sinaiko, Anna D, et al. "Out-of-Pocket Spending for Asthma-Related Care Among Commercially Insured Patients, 2004-2016." The journal of allergy and clinical immunology. In practice vol. 9,12 (2021): 4324-4331.e7. doi: https://doi.org/10.1016/j.jaip.2021.07.054
Sinaiko AD, Gaye M, Wu AC, Bambury E, Zhang F, Xu X, Wharam JF, Galbraith AA. Out-of-Pocket Spending for Asthma-Related Care Among Commercially Insured Patients, 2004-2016. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4324-4331.e7. doi: 10.1016/j.jaip.2021.07.054. Epub 2021 Sep 01. PMID: 34481128.
Copy Download .nbib Format: NLM
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research

Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W.
PMID: 34598946
Clin Cancer Res. 2021 Dec 15;27(24):6677-6686. doi: 10.1158/1078-0432.CCR-21-2199. Epub 2021 Oct 01.

PURPOSE: The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic PATIENTS AND METHODS: Patients had progressed after next-generation androgen receptor-directed and taxane-based therapies for...

Cite
Loehr A, Patnaik A, Campbell D, et al. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clin Cancer Res. 2021;27(24):6677-6686doi: 10.1158/1078-0432.CCR-21-2199.
Loehr, A., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., Zhang, J., Piulats, J. M., Hussain, A., Ryan, C. J., Merseburger, A. S., Daugaard, G., Heidenreich, A., Fizazi, K., Higano, C. S., Krieger, L. E., Sternberg, C. N., Watkins, S. P., Despain, D., Simmons, A. D., Dowson, M., Golsorkhi, T., Chowdhury, S., & Abida, W. (2021). Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6677-6686. https://doi.org/10.1158/1078-0432.CCR-21-2199
Loehr, Andrea, et al. "Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6677-6686. doi: https://doi.org/10.1158/1078-0432.CCR-21-2199
Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clin Cancer Res. 2021 Dec 15;27(24):6677-6686. doi: 10.1158/1078-0432.CCR-21-2199. Epub 2021 Oct 01. PMID: 34598946; PMCID: PMC8678310.
Copy Download .nbib Format: NLM
Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location.

JNCI cancer spectrum

Labadie JD, Harrison TA, Banbury B, Amtay EL, Bernd S, Brenner H, Buchanan DD, Campbell PT, Cao Y, Chan AT, Chang-Claude J, English D, Figueiredo JC, Gallinger SJ, Giles GG, Gunter MJ, Hoffmeister M, Hsu L, Jenkins MA, Lin Y, Milne RL, Moreno V, Murphy N, Ogino S, Phipps AI, Sakoda LC, Slattery ML, Southey MC, Sun W, Thibodeau SN, Van Guelpen B, Zaidi SH, Peters U, Newcomb PA.
PMID: 32923935
JNCI Cancer Spectr. 2020 May 19;4(5):pkaa042. doi: 10.1093/jncics/pkaa042. eCollection 2020 Aug.

BACKGROUND: Postmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor...

Cite
Labadie JD, Harrison TA, Banbury B, et al. Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location. JNCI Cancer Spectr. 2020;4(5):pkaa042doi: 10.1093/jncics/pkaa042.
Labadie, J. D., Harrison, T. A., Banbury, B., Amtay, E. L., Bernd, S., Brenner, H., Buchanan, D. D., Campbell, P. T., Cao, Y., Chan, A. T., Chang-Claude, J., English, D., Figueiredo, J. C., Gallinger, S. J., Giles, G. G., Gunter, M. J., Hoffmeister, M., Hsu, L., Jenkins, M. A., Lin, Y., Milne, R. L., Moreno, V., Murphy, N., Ogino, S., Phipps, A. I., Sakoda, L. C., Slattery, M. L., Southey, M. C., Sun, W., Thibodeau, S. N., Van Guelpen, B., Zaidi, S. H., Peters, U., & Newcomb, P. A. (2020). Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location. JNCI cancer spectrum, 4(5), pkaa042. https://doi.org/10.1093/jncics/pkaa042
Labadie, Julia D, et al. "Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location." JNCI cancer spectrum vol. 4,5 (2020): pkaa042. doi: https://doi.org/10.1093/jncics/pkaa042
Labadie JD, Harrison TA, Banbury B, Amtay EL, Bernd S, Brenner H, Buchanan DD, Campbell PT, Cao Y, Chan AT, Chang-Claude J, English D, Figueiredo JC, Gallinger SJ, Giles GG, Gunter MJ, Hoffmeister M, Hsu L, Jenkins MA, Lin Y, Milne RL, Moreno V, Murphy N, Ogino S, Phipps AI, Sakoda LC, Slattery ML, Southey MC, Sun W, Thibodeau SN, Van Guelpen B, Zaidi SH, Peters U, Newcomb PA. Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location. JNCI Cancer Spectr. 2020 May 19;4(5):pkaa042. doi: 10.1093/jncics/pkaa042. eCollection 2020 Aug. PMID: 32923935; PMCID: PMC7477374.
Copy Download .nbib Format: NLM
Adaptive phenotypic response to climate enabled by epigenetics in a K-strategy species, the fish .

Royal Society open science

Lighten J, Incarnato D, Ward BJ, van Oosterhout C, Bradbury I, Hanson M, Bentzen P.
PMID: 27853546
R Soc Open Sci. 2016 Oct 26;3(10):160299. doi: 10.1098/rsos.160299. eCollection 2016 Oct.

The relative importance of genetic versus epigenetic changes in adaptive evolution is a hotly debated topic, with studies showing that some species appear to be able to adapt rapidly without significant genetic change. Epigenetic mechanisms may be particularly important...

Cite
Lighten J, Incarnato D, Ward BJ, et al. Adaptive phenotypic response to climate enabled by epigenetics in a K-strategy species, the fish . R Soc Open Sci. 2016;3(10):160299doi: 10.1098/rsos.160299.
Lighten, J., Incarnato, D., Ward, B. J., van Oosterhout, C., Bradbury, I., Hanson, M., & Bentzen, P. (2016). Adaptive phenotypic response to climate enabled by epigenetics in a K-strategy species, the fish . Royal Society open science, 3(10), 160299. https://doi.org/10.1098/rsos.160299
Lighten, Jackie, et al. "Adaptive phenotypic response to climate enabled by epigenetics in a K-strategy species, the fish ." Royal Society open science vol. 3,10 (2016): 160299. doi: https://doi.org/10.1098/rsos.160299
Lighten J, Incarnato D, Ward BJ, van Oosterhout C, Bradbury I, Hanson M, Bentzen P. Adaptive phenotypic response to climate enabled by epigenetics in a K-strategy species, the fish . R Soc Open Sci. 2016 Oct 26;3(10):160299. doi: 10.1098/rsos.160299. eCollection 2016 Oct. PMID: 27853546; PMCID: PMC5098971.
Copy Download .nbib Format: NLM
T cell lymphomas in north Indian adults: Clinical features, diagnosis and treatment outcome in 20 patients.

The National medical journal of India

Bambery P, Kumar B, Varma S, Kaur U, Sehgal S, Kaur S, Deodhar SD.
PMID: 29751473
Natl Med J India. 1991 Jan-Feb;4(1):14-19.

Malignant diseases of T lymphocytes in adults are uncommon. Special difficulties arise both in establishing a diagnosis and in therapy. We describe our experience with 20 patients admitted to the Nehru Hospital, Chandigarh between 1980 and 1989. They had...

Cite
Bambery P, Kumar B, Varma S, et al. T cell lymphomas in north Indian adults: Clinical features, diagnosis and treatment outcome in 20 patients. Natl Med J India. 1991;4(1):14-19
Bambery, P., Kumar, B., Varma, S., Kaur, U., Sehgal, S., Kaur, S., & Deodhar, S. D. (1991). T cell lymphomas in north Indian adults: Clinical features, diagnosis and treatment outcome in 20 patients. The National medical journal of India, 4(1), 14-19.
Bambery, P, et al. "T cell lymphomas in north Indian adults: Clinical features, diagnosis and treatment outcome in 20 patients." The National medical journal of India vol. 4,1 (1991): 14-19.
Bambery P, Kumar B, Varma S, Kaur U, Sehgal S, Kaur S, Deodhar SD. T cell lymphomas in north Indian adults: Clinical features, diagnosis and treatment outcome in 20 patients. Natl Med J India. 1991 Jan-Feb;4(1):14-19. PMID: 29751473.
Copy Download .nbib Format: NLM
Churg-Strauss syndrome presenting as mononeuritis multiplex : a case report.

Neurology India

Singh G, Sawhney I, Parihar PS, Das A, Bambery P, Chopra JS.
PMID: 29542557
Neurol India. 1995 Oct-Dec;43(4):209-212.

A 25 year old female presented with mononeuritis multiplex and pulmonary symptoms. Investigations revealed the presence of marked peripheral blood eosinophilia. Skin and nerve biopsies were consistent with a diagnosis of Churg Strauss Syndrome. These were characterized by vasculitis...

Cite
Singh G, Sawhney I, Parihar PS, et al. Churg-Strauss syndrome presenting as mononeuritis multiplex : a case report. Neurol India. 1995;43(4):209-212
Singh, G., Sawhney, I., Parihar, P. S., Das, A., Bambery, P., & Chopra, J. S. (1995). Churg-Strauss syndrome presenting as mononeuritis multiplex : a case report. Neurology India, 43(4), 209-212.
Singh, G, et al. "Churg-Strauss syndrome presenting as mononeuritis multiplex : a case report." Neurology India vol. 43,4 (1995): 209-212.
Singh G, Sawhney I, Parihar PS, Das A, Bambery P, Chopra JS. Churg-Strauss syndrome presenting as mononeuritis multiplex : a case report. Neurol India. 1995 Oct-Dec;43(4):209-212. PMID: 29542557.
Copy Download .nbib Format: NLM
Socio-cultural factors in anorexia nervosa.

Indian journal of psychiatry

Chadda R, Malhotra S, Asad AG, Bambery P.
PMID: 21927222
Indian J Psychiatry. 1987 Apr;29(2):107-11.

Socio-cultural factors are one of the important variables involved in development of anorexia nervosa. The prevalence of the illness has shown a definite increase in last few decades. Certain other important sociocultural variables like familial interaction patterns, parental attitude...

Cite
Chadda R, Malhotra S, Asad AG, et al. Socio-cultural factors in anorexia nervosa. Indian J Psychiatry. 1987;29(2):107-11
Chadda, R., Malhotra, S., Asad, A. G., & Bambery, P. (1987). Socio-cultural factors in anorexia nervosa. Indian journal of psychiatry, 29(2), 107-11.
Chadda, R, et al. "Socio-cultural factors in anorexia nervosa." Indian journal of psychiatry vol. 29,2 (1987): 107-11.
Chadda R, Malhotra S, Asad AG, Bambery P. Socio-cultural factors in anorexia nervosa. Indian J Psychiatry. 1987 Apr;29(2):107-11. PMID: 21927222; PMCID: PMC3172455.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 75 entries